|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 252.16 USD | +0.10% |
|
+2.36% | +38.06% |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 12,976 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | 40.93% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 12,865 | 12,582 | 12,005 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | 41.81% | -2.2% | -4.59% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -128x | 44.1x | 17.3x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 13,356x | 43.8x | 15.4x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 2.8x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 13.2x | 8.12x | 5.66x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 13.1x | 7.88x | 5.24x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -116x | 53.2x | 22.6x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -127x | 36.5x | 13.1x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -213x | 34.5x | 17.7x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -0.47% | 2.89% | 5.65% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -1.971 | 5.713 | 14.56 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 985.3 | 1,598 | 2,291 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -111.2 | 236.3 | 531.6 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -101.2 | 344.4 | 914.7 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -102.3 | 315.2 | 812.6 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -110.7 | -393.8 | -970.8 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 252.16 | 252.16 | 252.16 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 51,460 | - | - |
| Announcement Date | 3/1/22 | 2/27/23 | 2/20/24 | 2/18/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -130.28x | 13.04x | -115.55x | -.--% | 12.96B | |
| 15.92x | 3.44x | 9.28x | 0.64% | 62.54B | |
| 26.98x | 5.45x | 15.6x | 0.59% | 55.22B | |
| 32.95x | 11.15x | 21.03x | -.--% | 40.9B | |
| -48.34x | 2.92x | 8.61x | 3.79% | 35.99B | |
| 31.58x | 3.43x | 10.37x | -.--% | 28.88B | |
| -6.41x | 8.8x | -5.38x | -.--% | 21.98B | |
| 15.2x | 2.66x | 8.22x | -.--% | 19.93B | |
| 49.02x | 5.22x | 37.44x | -.--% | 16.95B | |
| 24.09x | 4.99x | 13.47x | -.--% | 15.87B | |
| Average | 1.07x | 6.11x | 0.31x | 0.5% | 31.12B | |
| Weighted average by Cap. | 8.65x | 5.65x | 7.41x | 0.67% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- Valuation Axsome Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
